Project Grant R01AI187178
- This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,456,732 to support research on Toxoplasma gondii infection in people living with HIV/AIDS (PLWHA). The research aims to understand the mechanisms behind the parasite's ability to cause latent infections in the central nervous system and reactivate, leading to toxoplasma encephalitis - a significant cause of...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $817,730 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Vermont & State Agricultural College. The grant, awarded on July 9, 2025, supports the development of new tools to study how the Toxoplasma gondii parasite delivers its "effector" proteins into host cells during the invasion process. This research aims to understand the mechanisms by which T....
- This Project Grant award of $427,604 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to elucidate the molecular mechanisms of conoid extrusion in the pathogen Toxoplasma gondii. The goal is to reconstitute the core elements of the parasite's apical complex, including actin, myosin, and a formin, in vitro to gain a mechanistic understanding of how the conoid structure is extruded...
- This $423,500 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 22, 2025. The grant supports research to identify the molecular targets of the anti-parasitic compound Tartrolon E and determine if inhibition of the identified target proteins mediates the compound's broad anti-apicomplexan activity. The research aims to characterize the role of two rhoptry proteins,...
- This federal Project Grant award of $563,513.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The funding supports research at Arizona State University to investigate the patterning, growth, and maturation of the cortical microtubules in Toxoplasma, a unicellular parasite that causes diseases such as toxoplasmosis. The research aims to explore the initiation of patterning...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $454,036 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Irvine (UCI). The grant, titled "Microglial Immunity in Toxoplasmic Encephalitis", will support research to determine the role of brain-resident microglia cells in immune defense against the Toxoplasma gondii parasite, which commonly infects HIV/AIDS patients and can lead to...
- The Project Grant award of $135,315.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to investigate the impact of Toxoplasma gondii infection on the regulatory T cell (Treg) population in mice. The study aims to enhance understanding of the rebuilding process and long-term effects of the Treg collapse induced by acute T. gondii infection. The research will...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $847,000 Project Grant through the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Kentucky Research Foundation. The purpose of this 2.5-year award, beginning July 2025, is to investigate the protective roles of the CD180 and NOD1 molecules in the immune response against cerebral Toxoplasma gondii infection. The research aims to better understand how these pathogen-associated molecular...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $435,875 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Merced. The grant, titled "Interrogating NFKBID Dependent Humoral Immunity to Toxoplasma gondii", seeks to understand the mechanisms by which the transcriptional regulator IKBNS (encoded by NFKBID) mediates protective immunity against the parasitic infection Toxoplasma gondii. The...
- This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA Program 93.855 - Allergy and Infectious Diseases Research, will support research to investigate the genetic mechanisms that determine host susceptibility to low virulence strains of the Toxoplasma gondii parasite in mice. The $269,054 award, effective November 8, 2024 through October 31, 2026, will enable researchers at the University of California, Merced to leverage the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $603,601 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Regents of the University of Michigan to develop novel protease inhibitors to treat chronic Toxoplasma gondii infection. The goal is to eliminate tissue cysts of the Toxoplasma parasite, which can reactivate and cause ocular toxoplasmosis, a leading cause of infectious posterior uveitis that impairs vision in approximately 3,600 Americans annually. The 5-year project aims to: 1) create a computational model of the Toxoplasma protease to guide discovery of new inhibitor compounds, 2) optimize the potency, pharmacokinetics, and selectivity of lead inhibitor compounds, and 3) eradicate chronic Toxoplasma infection in a mouse model of intravitreal treatment. Successful completion of this project will advance one or more promising drug candidates for further development to address this unmet medical need.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $603.6k | 7/30/25 |